IRIS UniCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.759
AS - Asia 3.606
EU - Europa 2.881
SA - Sud America 850
AF - Africa 100
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.227
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.665
SG - Singapore 1.563
CN - Cina 951
BR - Brasile 679
DE - Germania 629
SE - Svezia 496
IT - Italia 459
UA - Ucraina 333
VN - Vietnam 323
FR - Francia 245
IE - Irlanda 194
GB - Regno Unito 164
ID - Indonesia 137
IN - India 117
HK - Hong Kong 111
FI - Finlandia 94
RU - Federazione Russa 92
JP - Giappone 68
AR - Argentina 56
TR - Turchia 48
IQ - Iraq 42
CA - Canada 39
BD - Bangladesh 37
KR - Corea 28
MX - Messico 27
NL - Olanda 27
ZA - Sudafrica 25
PK - Pakistan 23
AT - Austria 22
EC - Ecuador 22
ES - Italia 22
CL - Cile 20
IR - Iran 20
SA - Arabia Saudita 19
PE - Perù 18
BE - Belgio 17
CO - Colombia 17
PH - Filippine 17
AU - Australia 16
PL - Polonia 16
EG - Egitto 15
CH - Svizzera 14
VE - Venezuela 14
PY - Paraguay 12
TH - Thailandia 12
MY - Malesia 11
CI - Costa d'Avorio 10
NZ - Nuova Zelanda 10
UZ - Uzbekistan 10
KE - Kenya 9
MA - Marocco 9
CZ - Repubblica Ceca 8
UY - Uruguay 8
BH - Bahrain 7
JO - Giordania 7
OM - Oman 7
RO - Romania 7
TN - Tunisia 7
AZ - Azerbaigian 6
DZ - Algeria 6
ET - Etiopia 6
IL - Israele 6
AE - Emirati Arabi Uniti 5
KZ - Kazakistan 5
NP - Nepal 5
BO - Bolivia 4
CR - Costa Rica 4
HN - Honduras 4
JM - Giamaica 4
KW - Kuwait 4
LT - Lituania 4
LV - Lettonia 4
NO - Norvegia 4
SI - Slovenia 4
SN - Senegal 4
AL - Albania 3
CG - Congo 3
DO - Repubblica Dominicana 3
MK - Macedonia 3
NI - Nicaragua 3
PT - Portogallo 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
A1 - Anonimo 2
BY - Bielorussia 2
GE - Georgia 2
GT - Guatemala 2
HU - Ungheria 2
LI - Liechtenstein 2
MD - Moldavia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
Totale 11.209
Salva come PNG Salva come JPEG
Città #
Singapore 754
Ashburn 475
Chandler 408
San Jose 356
Beijing 221
Jacksonville 187
Dublin 179
San Mateo 156
Nanjing 134
Jakarta 115
Hangzhou 103
Hong Kong 96
Ho Chi Minh City 95
Lauterbourg 95
Wilmington 94
Cattolica 87
Woodbridge 81
Rome 79
Hanoi 75
Boston 73
Ann Arbor 70
Tokyo 64
Lawrence 63
Milan 63
Los Angeles 61
Moscow 53
Hefei 52
Houston 50
Menlo Park 50
São Paulo 47
Redwood City 45
New York 43
Nanchang 41
St Louis 41
Munich 40
Dearborn 39
Frankfurt am Main 37
Fairfield 36
Princeton 35
Chicago 34
Dallas 33
Seattle 31
Santa Clara 28
Bremen 26
Mountain View 26
Redmond 26
Shenyang 25
Boardman 24
Buffalo 23
Hebei 22
Kunming 22
Lancaster 21
Izmir 20
Rio de Janeiro 20
Da Nang 19
Paris 19
Tianjin 19
Haiphong 18
Bareggio 17
Brussels 17
Guangzhou 17
Helsinki 17
Belo Horizonte 16
Kent 16
Brasília 15
London 15
Seoul 15
Curitiba 14
Guarulhos 14
Hyderabad 14
Johannesburg 13
Dhaka 12
Norwalk 12
Nuremberg 12
University Park 12
Augusta 11
Baghdad 11
Jiaxing 11
Leawood 11
Lima 11
Nürnberg 11
Porto Alegre 11
Abidjan 10
Denver 10
Detroit 10
Hounslow 10
Philadelphia 10
Vienna 10
Amsterdam 9
Atlanta 9
Cairo 9
Campinas 9
Council Bluffs 9
Orem 9
Shanghai 9
Stockholm 9
Tashkent 9
Ankara 8
Biên Hòa 8
Brooklyn 8
Totale 5.739
Salva come PNG Salva come JPEG
Nome #
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 221
Antiplatelet agents for the treatment and prevention of atherothrombosis 214
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 193
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 188
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 177
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 171
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 171
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 168
Low-dose aspirin for the prevention of atherothrombosis 168
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 161
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 160
Nutraceuticals in diabetes and metabolic syndrome. 159
Increased thromboxane biosynthesis in essential thrombocythemia. 153
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 151
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 146
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 143
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 141
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 140
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 138
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 138
The coxibs, selective inhibitors of cyclooxygenase-2 137
Platelet activation and atherothrombosis 136
Drug insight: aspirin resistance- fact or fashion 132
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 132
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 128
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 128
Aspirin: promise and resistance in the new millennium. 127
Determinants of the interindividual variability in response to antiplatelet drugs. 125
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 123
Non-steroidal anti-inflammatory drugs 120
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 119
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 118
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 118
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 117
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 117
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 117
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 117
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 116
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 113
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 112
Platelet progenitors: the hidden drug target 112
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 112
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 111
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 110
The future of antiplatelet therapy in cardiovascular disease 109
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 108
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 108
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 108
Cigarette smoking knowledge and perceptions among students in four italian medical schools 108
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 105
Fourth universal definition of myocardial infarction (2018) 105
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 104
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 102
The role of aspirin in cancer prevention 102
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 99
Aspirin and Other COX-1 Inhibitors 99
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 99
Nonsteroidal antiinflammatory drugs: past, present and future 98
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 97
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 97
Aspirin, 110 years later 96
Determinants of platelet activation in Alzheimer's disease. 96
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 96
Aspirin 95
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 93
Mechanisms, consequences, and prevention of coronary graft failure 93
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 92
Aspirin 91
Measurement of Thromboxane Biosynthesis in Health and Disease 91
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 88
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 88
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 87
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 84
Prostanoids, aspirin and related compounds 84
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 82
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 82
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 82
Diabetes: Does aspirin increase the risk of major bleeds? 80
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 80
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 79
The P2Y12 receptor: no active metabolite, no party 79
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 79
Aspirin at 120: Retiring, recombining, or repurposing? 79
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 78
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 77
Precision antiplatelet therapy 76
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 74
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 73
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 73
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 73
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 72
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 72
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 69
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 69
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues 68
Nonsteroidal anti-inflammatory drugs and the heart 67
Antiplatelet Therapy 65
Less Thromboxane, Longer Life 64
Aspirin and Cancer 63
Platelet activation in obese women: role of inflammation and oxidant stress 61
Totale 11.036
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021171 0 0 0 0 0 0 0 0 0 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/20251.520 34 41 123 51 103 43 32 116 240 135 301 301
2025/20264.080 680 125 329 532 631 212 751 211 271 338 0 0
Totale 11.365